PT G20210A and factor V Leiden mutations and isolated limb perfusion-associated thrombosis in patients with soft tissue sarcoma

Aydan Eroğlu; Arzu Ulu; Selim Erekul; Hikmet Akgul; Nejat Akar

doi:10.1055/s-0037-1614279

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2004; 91(04): 837-838
DOI: 10.1055/s-0037-1614279

Letters to the Editor

Schattauer GmbH

PT G20210A and factor V Leiden mutations and isolated limb perfusion-associated thrombosis in patients with soft tissue sarcoma

Aydan Eroğlu

,

Arzu Ulu

,

Selim Erekul

,

Hikmet Akgul

,

Nejat Akar

Abstract

Volltext

Referenzen

References
1 Creech O, Krementz ET, Ryan RF. et al. Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit. Ann Surg 1958; 148: 616-32.
2 Eggermont AM, Koops HS, Klausner JM. et al. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicen-ter European experience. Ann Surg 1996; 224: 756-65.
3 Eroglu A, Kocaoglu H, Demirci S. et al. Isolated limb perfusion with cisplatin and doxorubicin for locally advanced soft issue sarcoma of an extremity. Eur J Surg Oncol 2000; 26: 213-21.
4 Klicks RJ, Vrouenraets BC, Nieweg OE. et al. Vascular complications of isolated limb perfusion. Eur J Surg Oncol 1998; 24: 288-91.
5 Eroğlu A, Özcan H, Eryavuz Y. et al. Deep venous thrombosis of the extremity diagnosed by color Doppler ultrasonography after isolated limb perfusion. Tumori 2001; 87: 187-90.
6 Fraker DL, Coit DG. Isolated perfusion of extremity tumors. In: Regional therapy of advanced cancer. Lotze MT, Rubin JT. (Eds), 333-349 Lippincott-Raven; Philadelphia: 1997
7 Dahlback B. Inherited thrombophilia: resistance to activated protein C as a pathogenic factor of venous thromboembolism. Blood 1995; 85: 607-14.
8 Bertina RM, Koeleman BP, Koster T. et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-7.
9 Dahlback B. New molecular insights into the genetics of thrombophilia. Resistance to activated protein C caused by Arg 506 to Gin mutation in Factor V as pathogenic factor for venous thrombosis. Thromb Haemost 1995; 74: 139-48.
10 Poort SR, Rosendal FR, Reitsma PH. et al. common genetic variation in the 3’-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88: 3698-703.
11 Otterson GA, Monahan BP, Harold N. et al. Clinical significance of the FV:Q 506 mutation in unselected oncology patients. Am J Med 1996; 101: 406-12.
12 Sifontes MT, Nuss R, Hunger SP. et al. The factor V Leiden mutation in children with cancer and thrombosis. Br J Haematol 1997; 96: 484-9.
13 Haim N, Lanir N, Hoffman R. et al. Acquired activated protein C resistance is common in cancer patients and is associated with venous thromboembolism. Am J Med 2001; 110: 91-6.
14 Weitz IC, Israel VK, Liebman HA. Tamox-ifen-associated venous thrombosis and activated protein C resistance due to factor V Leiden. Cancer 1997; 79: 2024-7.
15 Wriht DK, Manos MM. Sample preparation from paraffin-embedded tissues. In: PCR protocols. Innis MA, Gelfand DH, Sninsky JJ, White TJ. (Eds), Academic Press; San Diego: 153-8 1990